Al's Comment:

 I am a little biased on this one as we gave them 3 grants - including our largest ever - to help get them to this point.  They will be  presenting 10 abstracts at next week's Society for Neuro-Oncology conference in New Orleans.  This experimental drug - Onc-201 is the first of it's class - a DRD2/ DRD3 antagonist. Early results were very impressive, and we are hoping they present exciting news next week!   

---

Posted on: 11/07/2018

ONC201 Investigator Meeting and Clinical Efficacy in H3 K27M-mutant Glioma to be Presented at Society for Neuro-Oncology Conference 

 

---

Click HERE to return to brain tumor news headlines.